Apr 18, 2019
Cadwalader is advising AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, on its definitive agreement to sell its NAMIC® fluid management portfolio to Medline Industries, Inc. for $167.5 million. The transaction is subject to customary closing conditions, including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The transaction consists of AngioDynamics’ NAMIC brand and its extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories. Additionally, AngioDynamics’ primary Glens Falls, New York manufacturing facility, including all related manufacturing jobs and the sales and marketing teams that support the NAMIC business, will be acquired by Medline as part of the transaction.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.
Medline is a manufacturer, distributor and solutions provider focused on improving the overall operating performance of healthcare. Medline works with both the country’s largest healthcare systems and independent facilities across the continuum of care to provide the clinical and supply chain resources required for long-term financial viability in delivering high quality care. Headquartered in Northfield, Ill., Medline has 20,000+ employees worldwide and does business in more than 90 countries.
The Cadwalader team was led by Corporate Group co-chair William Mills and Corporate partner Braden McCurrach and included Corporate associate Peter Bariso; Tax partners Linda Swartz and Edward Wei; Executive Compensation, Benefits & ERISA partner David Teigman and associate Nicholas LaSpina; Environmental counsel Bill White; and Antitrust partner Joel Mitnick and counsel Ngoc Pham Hulbig.
The Bank of England has initiated a review of its own exposure to LIBOR,
Scott Cammarn, Jonathan Watkins, Mark Chorazak, Aaron Lang
On 7 June 2019, Regulation (EU) 2019/876 (CRR II) was published in the Official Journal of the EU.